How Dangerous Is Pulmonary Hypertension in Pregnant Women?

Pulmonary arterial hypertension (PAH) poses an exceptionally high risk during pregnancy, with maternal mortality rates historically ranging from 30% to 56%. This life-threatening condition places extraordinary strain on the right ventricle due to elevated pulmonary vascular resistance—changes that are normally counterbalanced by systemic vasodilation in healthy pregnancies. In PAH, however, this compensatory mechanism fails, leading to progressive right heart failure, hypoxemia, and hemodynamic instability.

The physiological demands of pregnancy—including a 30–50% increase in cardiac output, plasma volume expansion, and decreased systemic vascular resistance—exacerbate the underlying pathophysiology of PAH. Labor and delivery represent particularly critical periods: uterine contractions cause transient but profound increases in pulmonary artery pressure, while pain, anxiety, and Valsalva maneuvers further elevate right ventricular afterload. Even postpartum hemorrhage or fluid shifts can trigger acute decompensation.

Given these risks, current international guidelines—including those from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC)—strongly advise against pregnancy in women with confirmed PAH. Preconception counseling is essential, and effective contraception must be emphasized. For patients who become pregnant despite counseling, multidisciplinary management involving cardiologists specializing in pulmonary hypertension, maternal-fetal medicine specialists, anesthesiologists, and intensive care teams is mandatory. Delivery should occur at a tertiary center with advanced cardiopulmonary support capabilities, and vaginal delivery with epidural analgesia is generally preferred over cesarean section to minimize hemodynamic fluctuations.

Emerging evidence suggests that targeted PAH therapies—such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin pathway agents—may improve outcomes when continued or initiated under strict supervision. Nevertheless, no PAH medication is FDA-approved for use in pregnancy, and benefit-risk assessments must be individualized. Close monitoring via echocardiography, biomarkers (e.g., NT-proBNP), and functional assessment remains critical throughout gestation and the puerperium.